Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
Earnings release
confidence 95%
filed 2026-08-13
EX-99.1
This exhibit is a presentation for an "Earnings Conference Call 2Q26" disclosing Suzano's second-quarter 2026 financial results. It contains detailed operational and financial metrics including Adjusted EBITDA (R$4.7 billion), Adjusted Free Cash Flow (R$3.3 billion), net debt (US$6.9 billion), leverage ratios, sales volumes, pricing data, and segment performance for pulp and paper/packaging businesses. The document explicitly states it covers 2Q26 results with comparisons to prior periods, making it a material earnings disclosure that would affect investor assessment of the registrant's financial performance.
View raw filing on EDGAR →
6-K
Debt Issuance
confidence 92%
filed 2026-08-13
ICICI Bank disclosed the assignment of credit ratings ('Baa3' by Moody's and 'BBB' by S&P Global) to USD 300 million Senior Unsecured Fixed Rate Notes issued under its USD 7.5 billion Global Medium Term Note Programme. This is a material debt issuance event — the creation of a direct financial obligation through the issuance of notes, with the rating assignment confirming completion of the pricing disclosed on August 6, 2026.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-08-13
This is a press release disclosing Arcos Dorados' second quarter 2026 financial results, dated August 13, 2026. The document reports total revenues of $1.3 billion (up 14.3% YoY), Adjusted EBITDA of $126.8 million (up 15.2% YoY), and net income of $45.0 million ($0.22 per share), all described as record or near-record results for a second quarter. This is a discrete earnings announcement, not a periodic financial report filing, and the results are material to investors assessing the company's operational and financial performance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-13
Item 2.02
This is a standard earnings release disclosing Q2 2026 financial results for Intellicheck, Inc., filed under Item 2.02 (Results of Operations and Financial Condition). The press release reports revenue of $5.9 million (up 16% YoY), net income of $0.7 million, and adjusted EBITDA of $1.1 million, along with complete financial statements and management commentary. The disclosure is material as it provides quarterly results that would affect a reasonable investor's assessment of the company's financial performance and operational trends.
View raw filing on EDGAR →
6-K
Dividend Distribution
confidence 98%
filed 2026-08-13
EX-99.1
The exhibit announces the ex-dividend date for a Q2 2026 dividend of USD 5.25 per common share, with trading ex-dividend beginning August 13, 2026 on the Oslo Stock Exchange and August 14, 2026 on the NYSE. This is a straightforward dividend distribution announcement that would materially affect shareholders' assessment of capital returns and the company's cash deployment policy.
View raw filing on EDGAR →
6-K
Earnings release
confidence 98%
filed 2026-08-13
EX-99.1
This exhibit is a press release announcing China Automotive Systems' unaudited financial results for the first six months ended June 30, 2026. It discloses record net sales of $412.5 million (up 20.1% YoY), net income attributable to parent company shareholders of $29.3 million (up 98.8% YoY), and diluted EPS of $0.97 (up 98.0% YoY), along with detailed financial statements and management commentary. This is a classic earnings release for an interim period, material to investors assessing the company's financial performance and trajectory.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-08-13
EX-99.2
This exhibit is a press release announcing Evotec's Q2 and H1 2026 financial results, including revenues of €143.5m (Q2) and €300.1m (H1), adjusted EBITDA of -€20.8m and -€42.7m respectively, and a significantly revised full-year 2026 outlook (€570-€610m revenues vs. prior €700-€780m; -€70 to -€105m EBITDA vs. prior €0-€40m). The material downward revision in guidance and negative EBITDA trajectory would affect a reasonable investor's assessment of the company's financial performance and recovery trajectory.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-08-13
Item 2.01
Global Net Lease completed its acquisition of Modiv Industrial on August 12, 2026, adding a $535 million primarily industrial portfolio through issuance of approximately 20.4 million GNL shares (1.975 shares per Modiv share) plus $42.3 million in cash for preferred stock. The transaction is immediately accretive to AFFO per share by 4% and increases industrial exposure to approximately 50% of the portfolio with an extended weighted average lease term from 5.7 to 6.6 years on a pro forma basis.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-08-13
EX-99.1
This exhibit is a press release announcing ProQR's second quarter 2026 operating and financial results, including Q2 net loss of €8.7 million, cash position of €117.1 million, and key clinical milestones (positive AX-0810 Phase 1 target engagement data establishing first clinical validation of the Axiomer platform). The document contains unaudited interim condensed consolidated financial statements (balance sheet, P&L, changes in equity) and is clearly a results announcement for the period ended June 30, 2026, making it an earnings_release rather than a periodic_quarterly report.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-08-13
Item 7.01
PTC Therapeutics announced its selection as the winning bidder to acquire ST-920, a BLA-stage AAV gene therapy for Fabry disease, from Sangamo Therapeutics in a competitive bankruptcy auction. The transaction includes $111 million upfront and up to $100 million in contingent milestone payments, with expected closing in late Q3 or early Q4 2026, subject to bankruptcy court approval and customary closing conditions.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-08-13
EX-99.2
This exhibit is a press release announcing ProQR's second quarter 2026 operating and financial results, including Q2 net loss of €8.7 million, cash position of €117.1 million, and key clinical milestones (AX-0810 Phase 1 target engagement data, AX-0811 CTA submission, financing of $59.2 million). The document explicitly states "ProQR Therapeutics N.V. (Nasdaq: PRQR)...today reported its financial and operating results for the second quarter ended June 30, 2026" and includes unaudited interim condensed consolidated financial statements (balance sheet, income statement, changes in equity). This is a discrete earnings announcement, not a periodic financial report filing.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 94%
filed 2026-08-13
Item 1.01
Vireo Growth entered into a senior secured asset-based revolving credit facility with Bank of Montreal on August 7, 2026, providing $65 million in initial commitments, expandable to $85 million and further to $105 million, with a five-year term secured by substantially all assets and bearing interest at SOFR plus 1.75%-2.00% or base rate plus 0.75%-1.00%. The facility is designed to refinance existing indebtedness, fund working capital, and finance acquisitions.
View raw filing on EDGAR →
8-K
M&A activity
confidence 97%
filed 2026-08-13
Item 2.01
Vireo Growth completed the acquisition of 17 Colorado retail cannabis dispensary assets (PharmaCann Transaction) on August 7, 2026, for approximately $48.7 million in consideration consisting of 3,004,751 subordinate voting shares and assumption of liabilities, expanding its Colorado retail footprint to 56 dispensary locations.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-08-13
Item 3.02
Vireo Growth issued approximately 3,004,751 subordinate voting shares as consideration in the PharmaCann acquisition, representing approximately $48.7 million in equity consideration in a transaction exempt from Securities Act registration under Section 4(a)(2) and Regulation D.
View raw filing on EDGAR →
6-K
Debt Issuance
confidence 92%
filed 2026-08-13
EX-99.1
Vertical Aerospace amended and restated its convertible note purchase agreement with Mudrick Capital Management on August 12, 2026, establishing a $35 million commitment to issue additional 10.00%/12.00% Convertible Senior Secured PIK Toggle Notes due 2030 under an existing indenture framework.
View raw filing on EDGAR →
6-K
Governance Other
confidence 92%
filed 2026-08-13
EX-99.2
Vertical Aerospace entered into a shareholder agreement with Mudrick Capital Management granting Mudrick board nomination and committee designation rights proportional to its shareholding (minimum one director), contemplating a board refreshment exercise that increases the board from 8 to 9 seats, with shareholder approval of Articles amendments required by September 15, 2026.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-08-13
EX-99.4
Vertical Aerospace amended and restated its Securities Purchase Agreement with YA II PN, Ltd. on August 12, 2026, for the sale of up to $250 million in Series A Convertible Preferred Shares convertible into Ordinary Shares in a private placement structured with multiple closings.
View raw filing on EDGAR →
6-K
Financial Other
confidence 45%
filed 2026-08-13
EX-99.3
Vertical Aerospace amended and restated the Certificate of Designations for Series A Convertible Preferred Shares, establishing terms for conversion rights, dividend mechanics, and ranking of the preferred equity instrument as part of its capital structure.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-13
Item 2.02
Zenas BioPharma reported Q2 2026 financial results for the quarter ended June 30, 2026, disclosing revenue of $1.0 million, R&D expenses of $62.9 million, G&A expenses of $15.7 million, net loss of $111.5 million, and cash position of $673.9 million.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-08-13
Item 5.02
The Board appointed Christy J. Oliger as a Class II director effective September 1, 2026, with assignment to two Board committees. Ms. Oliger brings 30+ years of biopharmaceutical commercial and operating experience, including senior roles at Genentech leading multi-billion-dollar product portfolios, which is material to the company's advancement toward commercialization.
View raw filing on EDGAR →
6-K
Debt Issuance
confidence 85%
filed 2026-08-13
EX-99.1
Recurrent Energy (Canadian Solar's subsidiary) announced the successful close of $695 million in project financing for the Cobalt Solar facility, comprising approximately $484 million in debt financing (construction and term loans, tax equity bridge loan, and letter of credit facility led by MUFG and Nord/LB) plus $211 million in tax equity investment from Wells Fargo. This represents a material creation of direct financial obligations for the registrant's subsidiary and is a significant capital event for the company's renewable energy project portfolio.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-08-13
EX-99.1
The controlling shareholder Ardagh Holdings S.A. has instructed advisers to prepare for a potential sale of Ardagh Metal Packaging S.A., with Evercore and Kirkland & Ellis appointed as financial and legal advisers. The disclosure explicitly states that "AHSA would sell some or all of the equity interests indirectly held in AMPSA to a third-party buyer" and contemplates a scenario where AHSA would acquire remaining ordinary shares to facilitate a complete sale. This constitutes a material M&A activity — a potential change of control or disposition — that would materially affect a reasonable investor's assessment of the registrant.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-13
Item 2.02
This is a standard earnings release disclosing quarterly financial results for Q2 2026 (quarter ended June 30, 2026). The filing includes condensed consolidated balance sheets, statements of operations with net loss of $6.9 million for the quarter, and per-share metrics. The press release was issued on August 13, 2026, and furnished as Exhibit 99.1, which is the typical format for Item 2.02 earnings disclosures. While the release also includes corporate updates on clinical trial progress, the primary disclosure is the financial results for the period.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-13
EX-99.1
This is a business update press release disclosing significant operational and strategic progress during H1 2026, including achievement of piloted transition flights with full-scale aircraft, successful public flight demonstrations at Farnborough Airshow, ecosystem partnerships (Near Earth Autonomy, Honeywell's Project VERTI-GO), UK Government discussions on £10 million production facility support, and approximately $100 million in financing commitments. While the document references that "The Company's H1 2026 financial results 6-K filing has been filed," this exhibit itself is a discrete operational and strategic announcement rather than the periodic financial report itself. The milestones disclosed—transition flights, regulatory integration participation, manufacturing facility progress, and funding commitments—are material operational developments that would affect a reasonable investor's assessment of the company's progress toward certification and commercialization, but do not fit neatly into specific event categories (not an earnings release, M&A, exec change, or other named type), making operational_other the most appropriate classification.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 92%
filed 2026-08-13
Collegium announced execution of a $50 million accelerated share repurchase (ASR) agreement with Jefferies LLC on August 12, 2026, as part of a $150 million share repurchase program authorized by the Board in July 2025. Share repurchases are a form of return of capital to shareholders and fall within the dividend_distribution category, which encompasses share-repurchase programs. The filing discloses the initial delivery of 1,556,420 shares (approximately 80% of expected total) and expected completion by Q4 2026.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-13
Item 2.02
Yesway issued a press release on August 13, 2026 announcing financial results for the second quarter ended June 30, 2026, disclosing net income of $29.7 million (up from $24.2 million), Adjusted EBITDA of $70.9 million (up 35% year-over-year), and increased full-year 2026 Adjusted EBITDA guidance to $235–$245 million. This is a standard quarterly earnings release furnished as Exhibit 99.1 under Item 2.02, materially affecting investor assessment of the registrant's operating performance and financial condition.
View raw filing on EDGAR →
6-K
Earnings release
confidence 92%
filed 2026-08-13
EX-99.3
This exhibit is a press release announcing NervGen's second quarter 2026 financial results, including cash position (C$86.8 million), R&D and G&A expenses, and net loss (C$29.2 million). The document explicitly states "NervGen Reports Second Quarter 2026 Financial Results" and provides detailed quarterly financial metrics. While the release also includes business updates (Phase 3 RESTORE study progress, leadership appointments), the primary disclosure is the quarterly earnings announcement, which is material to investors assessing the company's financial condition and runway.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-08-13
Item 5.02
Ms. Shelby Yohn resigned as Chief Financial Officer on August 13, 2026, after holding the position for only four months (since April 2, 2026). While she remains with the company as Director of Accounting and continues as Principal Financial and Accounting Officer, the principal disclosed action is her departure from the CFO role. The company has engaged an executive search firm to recruit a replacement CFO and retained a former CFO as consultant, indicating the CFO departure is the material event. The brevity of her tenure and the need for external recruitment suggest this is a significant management transition warranting disclosure.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-08-13
EX-99.1
This exhibit is a press release announcing Xunlei's unaudited financial results for the second quarter ended June 30, 2026. It discloses total revenues of US$102.7 million (up 38.9% YoY), gross profit of US$57.3 million, and a net loss from continuing operations of US$218.5 million (compared to net income of US$726.4 million in Q2 2025). The dramatic swing from profitability to loss, driven primarily by fair value changes in the company's long-term investment in Arashi Vision Inc., is material to investors' assessment of the company's financial performance and outlook.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-13
Item 2.02
MeiraGTx issued a press release on August 13, 2026 announcing financial results for the quarter ended June 30, 2026, disclosing Q2 2026 financial and operational results including cash position ($143.2 million), service revenue ($11.9 million), related-party service revenue ($104.9 million), and license revenue ($204.6 million). This is a standard quarterly earnings release furnished as Exhibit 99.1 under Item 2.02, meeting the definition of earnings_release.
View raw filing on EDGAR →
6-K
Earnings release
confidence 98%
filed 2026-08-13
EX-99.1
This is a press release announcing GDS Holdings' unaudited financial results for the second quarter ended June 30, 2026. The document discloses quarterly net revenue (RMB3,088.0 million, up 6.5% Y-o-Y), net income (RMB837.6 million vs. prior-year loss of RMB70.6 million), adjusted EBITDA, and operating metrics. The company also provides updated full-year 2026 guidance. This is a discrete earnings announcement, not a periodic financial report, and is material to investors assessing the registrant's financial performance and outlook.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-13
Item 2.02
Dogwood Therapeutics issued a press release on August 13, 2026 announcing financial results for the second quarter ended June 30, 2026, including R&D expenses of $3.2 million, G&A expenses of $1.6 million, a $9.2 million IPR&D impairment charge, and a net loss of $11.5 million ($0.34 per share). The filing explicitly states this is Item 2.02 disclosure with the press release incorporated as Exhibit 99.1, which is the standard format for quarterly earnings releases. The disclosure includes both operational highlights (clinical trial progress, FDA approvals, scientific advisory board appointment) and detailed financial statements, making it material to investors' assessment of the company's financial condition and progress.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-13
Item 2.02
zSpace issued a press release on August 13, 2026 announcing financial results for the fiscal quarter ended June 30, 2026, disclosing Q2 2026 revenue of $5.4 million, net income of $0.3 million (versus a net loss of $6.1 million in Q2 2025), and gross margin expansion to 56% from 43%. This is a standard quarterly earnings release furnished as Exhibit 99.1 under Item 2.02, and the results are material to investors as they show a significant swing to profitability and margin improvement.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-13
Item 2.02
This is a clear earnings release for Q2 2026 (quarter ended June 30, 2026). The Item 2.02 disclosure announces financial results including collections of $300.9 million, net income of $41.3 million, and EPS of $0.67, with the full press release furnished as Exhibit 99.1. The filing includes consolidated balance sheets and statements of operations, which are standard components of quarterly earnings announcements.
View raw filing on EDGAR →
8-K
Earnings release
confidence 97%
filed 2026-08-13
Item 2.02
MultiSensor AI Holdings issued a press release announcing its financial results for the second fiscal quarter ended June 30, 2026, disclosing Q2 2026 revenue of $1.7 million (19% growth), software revenue of $0.7 million (85% growth), and net loss of $2.5 million (26% improvement year-over-year), with condensed consolidated financial statements and management commentary provided.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-08-13
Item 8.01
Duke Energy consummated the issuance and sale of 40 million equity units (including 5 million from over-allotment exercise) on August 13, 2026, comprising stock purchase contracts and undivided beneficial ownership interests in 4.85% Remarketable Senior Notes due 2032 and 2036. The RSNs constitute direct financial obligations issued under supplemental indentures, representing the primary material financial obligation of this transaction.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-13
Item 2.02
ProMIS Neurosciences issued a press release on August 13, 2026, reporting financial results for the quarter ended June 30, 2026, including a net loss of $11.7 million, cash position of $53.4 million, and cash runway through 2027. The filing explicitly states under Item 2.02 that the Company "issued a press release...reporting its financial condition and financial results as of and for the quarter ended June 30, 2026," with the press release furnished as Exhibit 99.1 and incorporated by reference. The exhibit contains condensed consolidated balance sheets and statements of operations for the periods ended June 30, 2026 and 2025, which are standard quarterly financial results disclosures.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-13
Item 2.02
This is a standard quarterly earnings release for Q2 2026 ended June 30, 2026, furnished as a press release exhibit (EX-99.1) under Item 2.02. The filing discloses financial results including revenue ($0), operating expenses ($42.9M for Q2), and net loss ($40.7M or $0.70 per share), along with cash position ($237.9M) and financial outlook. While the press release also includes material regulatory and clinical updates regarding Deramiocel's FDA review and HOPE-3 results, the Item 2.02 classification centers on the financial results disclosure itself.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-13
Item 2.02
AudioEye issued a press release on August 13, 2026, reporting financial results for the fiscal quarter ended June 30, 2026 (Q2 2026). The disclosure includes quarterly revenue ($10.7M, up 9% YoY), ARR ($42.3M, up 11% YoY), adjusted EBITDA ($3.0M, a record), adjusted EPS ($0.23), and full-year 2026 guidance. This is a standard quarterly earnings release furnished under Item 2.02, with the press release attached as Exhibit 99.1.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 98%
filed 2026-08-13
Item 8.01
RLI's Board of Directors declared a regular quarterly cash dividend of $0.18 per share, payable September 15, 2026. This is a routine but material dividend distribution to shareholders. The filing explicitly states the dividend amount, record date, and payment date, and the press release notes RLI has increased dividends for 51 consecutive years, making this a significant capital allocation event material to investors.
View raw filing on EDGAR →
8-K
Earnings release
confidence 97%
filed 2026-08-13
Item 2.02
KULR Technology Group disclosed Q2 2026 quarterly earnings results showing significant financial deterioration: revenue declined 43% year-over-year to $2.08M, gross margin was negative 31%, operating loss increased 19% to $11.2M, and net loss was $22.0M or $0.47 per share compared to prior-year net income of $0.22 per share, with material non-cash fair value losses on bitcoin holdings contributing to the results.
View raw filing on EDGAR →
6-K
Debt Issuance
confidence 85%
filed 2026-08-13
EX-99.1
This Third Supplemental Indenture dated August 13, 2026 amends the existing indenture for Gildan's $600 million 4.700% Notes due 2030 and $600 million 5.400% Notes due 2035 (originally issued October 7, 2025). The document adds three new guarantors (HBI Branded Apparel Enterprises LLC, Hanes Jiboa Holdings LLC, and Hanesbrands El Salvador LTDA) who unconditionally guarantee the Notes on a senior basis. While technically a supplemental indenture rather than a new debt issuance, this amendment materially modifies the debt structure by expanding the guarantor base, which affects the credit quality and obligations under the existing $1.2 billion debt facility and is material to investors.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-13
Item 2.02
This is a clear earnings release for Q2 2026 ended June 30, 2026. The filing discloses quarterly financial results including total revenue of $46.5 million (up 12.1% YoY), net income of $0.3 million (vs. prior-year loss of $0.7 million), and key operational metrics such as AuM growth of 13.4% to $31.6 billion. The press release is furnished as Exhibit 99.1 and contains consolidated balance sheet and statement of operations, making this a material earnings disclosure under Item 2.02.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 92%
filed 2026-08-13
EX-99.1
Michael Smith, the Company's Chairman, has been appointed as interim Chief Executive Officer and Chief Financial Officer, replacing Samuel Morrow who transitions to a non-executive director role. This is a material executive appointment affecting the Company's top leadership structure and operational control during the interim period while the Company seeks permanent candidates for these critical roles.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-08-13
Item 8.01
ON Semiconductor discloses a material acquisition of Synaptics Incorporated pursuant to an Agreement and Plan of Reorganization entered into on June 25, 2026. The filing reports that the FTC granted early termination of the HSR Act waiting period on August 12, 2026, removing a key closing condition. The transaction is expected to close in mid-2027 and represents a significant change of control event material to investors.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-08-13
Item 1.01
Opendoor entered into subscription agreements on August 12, 2026 to issue $650 million aggregate principal amount of 0.00% Convertible Senior Notes due 2030, a material creation of a new direct financial obligation. The transaction includes concurrent share repurchase ($158 million) and capped call transactions designed to minimize dilution.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-08-13
Item 1.01
Cannabist Co Holdings Inc. entered into definitive agreements to sell its cannabis cultivation, manufacturing, and retail operations in Maryland to Free State Botanicals for up to $13.75 million in cash, plus a concurrent real estate sale with debt assumption. The transaction requires CCAA court approval and regulatory clearance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 99%
filed 2026-08-13
Item 2.02
Tapestry issued a press release on August 13, 2026 announcing financial results for its fourth fiscal quarter and full year ended June 27, 2026. The disclosure includes detailed financial highlights (revenue of $8.0 billion, GAAP diluted EPS of $7.27, non-GAAP diluted EPS of $7.05), brand performance metrics, regional results, and forward guidance for fiscal 2027. This is a standard quarterly/annual earnings release disclosure under Item 2.02, material to investors assessing the company's financial performance and outlook.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-13
Item 7.01
IREN announced delivery and acceptance of Horizon 1 by Microsoft and achievement of NVIDIA Exemplar Cloud Status on GB300 NVL72. This is a material operational milestone demonstrating execution on the company's $9.7bn five-year Microsoft contract and its AI infrastructure expansion strategy. While the disclosure is operational in nature (project delivery, certification achievement), it does not fit the specific categories of M&A, workforce reduction, or other named operational types; it is best classified as an operational milestone or contract performance achievement.
View raw filing on EDGAR →
8-K
Terminal Other
confidence 95%
filed 2026-08-13
Item 8.01
The board determined the Company cannot consummate a business combination within the required timeframe and has decided to liquidate and dissolve the Company, cease operations except for winding up, and redeem all outstanding Public Shares from the Trust Account. This is a terminal event materially threatening the registrant's continued existence—the Company is dissolving and returning capital to shareholders, which is the ultimate outcome for a blank-check acquisition vehicle that failed to complete its business combination.
View raw filing on EDGAR →